Metrics Contract Services Adds to Business Development Team
May 18, 2020, Greenville, N.C. – Metrics Contract Services (Metrics), a division of Mayne Pharma, is pleased to announce that Ivelisse Ruiz has joined the company as Business Development Executive with the Business Development Team.
As a member of the Business Development Team, Mrs. Ruiz will focus on developing new client opportunities primarily in the US Southeast. Mrs. Ruiz brings nearly a decade of technical and commercial business development experience in the pharmaceutical industry. Prior to joining Metrics Contract Services, she was a technical account manager at IMCD US LLC, a distributor of specialty pharmaceutical ingredients that was formerly known as Mutchler Pharmaceutical Ingredients, Inc. Mrs. Ruiz also worked as an event coordinator for ExcipientFest, Inc., an international expo exclusively devoted to excipients.
Director of Business Development Tom Salus, said, “We are excited to welcome Ivelisse to our Business Development Team. Her commitment to developing trusted partnerships with clients and passion for account service is an excellent fit with our organization.”
A graduate of the University of Tampa, Mrs. Ruiz holds a BA in Industrial/Organizational Psychology. She earned her MBA from Universidad del Turabo, Gurabo, Puerto Rico.
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.
Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialized in numerous products that have been marketed around the world.
Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in formulation of complex oral and topical dose forms including potent compounds, modified-release products and inherently unstable compounds. For further information, visit www.maynepharma.com.